Clik here to view.
Syndax Pharma Seeks to Reprogram Tumor Cells to Treat Breast Cancer
Ryan McBride Women lose a valuable weapon against their breast tumors when the potency of hormone therapy fades. But what if there was a way to “reprogram” breast tumor cells to be receptive to...
View ArticleClik here to view.
MIT Cancer Research Star Tyler Jacks Takes Closing Keynote Role at Xconomy Forum
Luke Timmerman We like to sweeten the pot around here, adding world-class speakers to our Xconomy Forums every chance we get. And today I’m psyched to announce that Tyler Jacks, a world-renowned...
View ArticleClik here to view.
Epizyme Nabs $650M Deal With Glaxo To Hunt for Epigenetic Drugs
Luke Timmerman Cambridge, MA-based Epizyme has found its first big partner to help support its work in hunting for new drugs based on the emerging science around epigenetics. Epizyme said today it has...
View ArticleClik here to view.
$12.7M Blows in for Wind Power Holdings, Epizyme Forges Alliance with...
Rebecca Zacks Dealmaking activity in New England’s tech and life sciences sectors continued at a blizzardy pace this week. Hold on to your hat… —Marlborough, MA-based biofuels developer Qteros raised...
View ArticleClik here to view.
Epizyme Takes $6M Upfront in Cancer Drug Deal with Eisai
Ryan McBride Cambridge, MA-based Epizyme has nabbed another pharmaceutical partnership. Two months after announcing a deal worth as much as $650 million with GlaxoSmithKline (NYSE:GSK), the startup...
View ArticleClik here to view.
Epizyme Nabs Eisai Deal, Termeer Could Make $221.2M From Genzyme Buyout,...
Erin Kutz We saw some meaty stories on Boston-area drug developers this week, as well as headlines about funding for newer healthcare and health IT startups. —Imprivata of Lexington, MA, is working on...
View ArticleClik here to view.
World Energy Backs Retroficiency, American Superconductor Gets Finnish Firm,...
Erin Kutz This week’s deal news spanned companies working on marketing, energy, daily deals, medical devices, and beauty products. —Retroficiency, a Boston-based software-as-a-service firm focused on...
View ArticleClik here to view.
Epizyme, Riding High on Two Big Pharma Deals, Zeroes in on Personalized...
Luke Timmerman Big Pharma companies are not exactly known for being nimble, but they have made a couple of quick bam-bam moves in succession to land deals with Cambridge, MA-based Epizyme. The company...
View ArticleClik here to view.
Vertex CF Drug Delivers, Follica Patent Application Reveals Tech, RXi Buys...
Erin Kutz This week we’ve seen news of acquisitions and funding, as well as longer articles on strategy and research moves for New England’s life sciences firms. —BL Healthcare, a provider of...
View ArticleClik here to view.
Constellation Pharma Raises More Money and Further Defines Pipeline
Arlene Weintraub When Xconomy last checked in on Cambridge, MA, epigenetics startup Constellation Pharmaceuticals, in the fall of 2009, CEO Mark Goldsmith declined to disclose details about the...
View ArticleClik here to view.
VC Investment in MA Companies Falls Back to Earth (from $1B to $505M): Top 10...
Gregory T. Huang Here comes another venture capital downturn. Maybe. That’s my not-so-definitive take after looking at the VC investment numbers for Massachusetts in the third quarter of 2011, which...
View ArticleClik here to view.
BIO Investor Forum Roundup: Immune Design, Sorbent Therapeutics, Epizyme
Luke Timmerman The best thing about coming to the BIO Investor Forum in San Francisco every year is the schmoozing with folks from all over the country in one place. The worst thing? There’s not much...
View ArticleClik here to view.
Join Us for a Tweetchat Monday on Biotech Startups
Luke Timmerman [Update: 10:50 am PT] Biotech VCs had their chance to vent on Twitter last week about the sad state of affairs in financing startups, and now it’s time for the entrepreneurs to take...
View ArticleClik here to view.
Epizyme Gets $90M in Epigenetics Partnership with Celgene
Arlene Weintraub Cambridge, MA-based Epizyme said today that it has formed a strategic partnership with an international subsidiary of Summit, NJ-based Celgene (NASDAQ: CELG). The two companies will...
View ArticleClik here to view.
Genzyme, Epizyme, & Rib-X Among the Week’s Life Sciences Newsmakers
Erin Kutz We’ve seen clinical trial, funding, partnership, and IPO news from local drug developers this week. —Genzyme, the Cambridge, MA-based unit of Sanofi (NYSE: SNY) shared more positive data...
View ArticleClik here to view.
Gladstone, Sage Bionetworks Top ‘Best Places to Work’ List
Luke Timmerman A couple of small West Coast research centers, the J. David Gladstone Research Institutes in San Francisco, and Sage Bionetworks in Seattle, have gotten kudos as the “Best Places to...
View ArticleClik here to view.
The Year In New York Biotech—Still Trying to Make It Here
Catherine Arnst It’s been a year and a half since Xconomy added New York to the cities it covers. I came on as New York Editor in October, taking over from Arlene Weintraub, who pioneered coverage...
View ArticleClik here to view.
Brook Byers of Kleiner Perkins on Sticking With Healthcare
Luke Timmerman Kleiner Perkins Caufield & Byers is one of the kingpins of venture capital, best known as the firm that got in on the ground floor at Google, Amazon, Genentech and plenty of other...
View ArticleClik here to view.
Presage Snags $13M from Celgene to Pick Winning Cancer Drug Combos
Luke Timmerman Seattle-based Presage Biosciences has found another big partner that thinks it can help separate the winners from the losers in early cancer drug development, before the really big...
View ArticleClik here to view.
East Coast Life Sciences Roundup: Thermo, Alkermes, Acorda, Epizyme
Bernadette Tansey One big story—the Boston Marathon bombing—dominated the news this week. Boston’s healthcare system rose to the challenge of treating so many injured victims, as reported in this...
View Article
